Glenmark Pharmaceuticals Monday said it has received final approval from the US health regulator for antiplatelet agents Aspirin and extended-release Dipyridamole capsules. The approved product is a generic version of Aggrenox capsules of Boehringer Ingelheim Pharmaceuticals Inc. Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Aspirin and extended-release Dipyridamole capsules in the strength of 25 mg/200 mg, the company said in a BSE filing. Citing IQVIA sales data, Glenmark said, the Aggrenox capsules, 25 mg/200 mg market achieved annual sales of approximately USD 165.6 million in the 12-month period ended March 2019. The company said its current portfolio consists of 155 products authorised for distribution in the US and 58 Abbreviated New Drug Application (ANDA's) pending approval with the USFDA. Shares of Glenmark Pharma were trading 0.03 per cent higher at Rs 559.20 apiece on the BSE.
from Latest News http://bit.ly/2QpFbOl
https://ift.tt/eA8V8J http://bit.ly/2SdCH5P
Home
Business
Business News
Business Standard
Latest News
Glenmark Pharma receives final approval from USFDA for antiplatelet drug
Monday, May 27, 2019
Related Posts:
JSW Energy reorganises itself into 'Green' and 'Grey' businessesThe company said that all the existing and upcoming renewable energy b… Read More
PM Modi wanted Asia's biggest airport in Uttar Pradesh: ScindiaScindia said the airport, located in Jewar in Gautam Buddh Nagar distr… Read More
Worst-ever Covid variant will make vaccines 40% less effective: UKUK Health Secretary Sajid Javid sounded an alarm over the new 'worst-e… Read More
Tata in talks to set up $300-mn semiconductor assembly unit: ReportTata Group is in talks with with Tamil Nadu, Karnataka and Telangana a… Read More
0 comments: